{
    "citations": [
        {
            "footnote": 38,
            "title": "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.",
            "in_text_citation": "Baden et al., 2020"
        },
        {
            "footnote": 43,
            "title": "A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.",
            "in_text_citation": "Chu et al., 2021"
        },
        {
            "footnote": 46,
            "title": "Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.",
            "in_text_citation": "Goepfert et al., 2021"
        },
        {
            "footnote": 39,
            "title": "Safety and efficacy of NVX-CoV2373 COVID-19 vaccine.",
            "in_text_citation": "Heath et al., 2021"
        },
        {
            "footnote": 44,
            "title": "Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine.",
            "in_text_citation": "Keech et al., 2020"
        },
        {
            "footnote": 45,
            "title": "Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.",
            "in_text_citation": "Li et al., 2021"
        },
        {
            "footnote": 47,
            "title": "Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant.",
            "in_text_citation": "Madhi et al., 2021"
        },
        {
            "footnote": 48,
            "title": "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.",
            "in_text_citation": "Polack et al., 2020"
        },
        {
            "footnote": 41,
            "title": "Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.",
            "in_text_citation": "Richmond et al., 2021"
        },
        {
            "footnote": 42,
            "title": "Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine.",
            "in_text_citation": "Sadoff et al., 2021"
        },
        {
            "footnote": 49,
            "title": "Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant.",
            "in_text_citation": "Shinde et al., 2021"
        },
        {
            "footnote": 40,
            "title": "Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates.",
            "in_text_citation": "Walsh et al., 2020"
        }
    ]
}